Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 12, 2012, Pages 1760-1767

  Rinaldi, F ^a   Calabrese, M ^a   Seppi, D ^a   Puthenparampil, M ^a   Perini, P ^a   Gallo, P ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

cortical atrophy; cortical lesions; Multiple sclerosis; natalizumab; relapsing remitting multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; NATALIZUMAB;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX LESION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT OUTCOME;

EID: 84871601043     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512447704     Document Type: Article

References (38)

1. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008 ; 7: 538-547
2. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
3. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
4. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 ; 8: 254-260
5. Putzki N, Yaldizli O, Bühler R, et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol. 2010 ; 63: 101-106
6. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002 ; 15: 239-245
7. Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain. 1999 ; 122: 17-26
8. Peterson JW, Bö L, Mörk S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001 ; 50: 389-400
9. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 ; 128: 2705-2712
10. Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 2005 ; 236: 254-260
11. Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol. 2007 ; 64: 1416-1422
12. Calabrese M, De Stefano N, Atzori M, et al. Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol. 2008 ; 255: 581-586
13. Calabrese M, Filippi M, Rovaris M, et al. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler. 2009 ; 15: 36-41
14. Calabrese M, Rocca MA, Atzori M, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology. 2009 ; 72: 1330-1336
15. Roosendaal SD, Moraal B, Pouwels PJ, et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler. 2009 ; 15: 708-714
16. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol. 2009 ; 66: 1144-1150
17. Calabrese M, Rocca MA, Atzori M, et al. A three-year MRI study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol. 2010 ; 67: 376-383
18. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain. 2004 ; 127: 1101-1107
19. Sailer M, Fischl B, Salat D, et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain. 2003 ; 126: 1734-1744
20. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001 ; 70: 773-780
21. Rinaldi F, Calabrese M, Seppi D, et al. Natalizumab prevents the accumulation of cortical lesions in relapsing-remitting multiple sclerosis: a preliminary report. Neurol Sci. 2010 ;:
22. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
23. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 ; 39: 285-294
24. Randomised double-blind placebo-controlled study of interferon I-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 ; 352: 1498-1504
25. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998 ; 50: 701-708
26. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 ; 8: 889-897
27. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 ; 7: 903-914
28. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
29. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 1991 ; 54: 683-688
30. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000 ; 97: 11050-11055
31. Calabrese M, Battaglini M, Giorgio A, et al. Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology. 2010 ; 75: 1234-1240
32. Khoury S, Bakshi R. Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. Ann Neurol. 2010 ; 68: 778-779
33. Frank JA, Richert N, Bash C, et al. Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology. 2004 ; 62: 719-725
34. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 ; 68: 1390-1401
35. Popescu BF, Bunyan RF, Parisi JE, et al. A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology. 2011 ; 76: 1705-1710
36. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011 ; 365: 2188-2197
37. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66
38. Martínez-Yélamos S, Martínez-Yélamos A, Martín Ozaeta G, et al. Regression to the mean in multiple sclerosis. Mult Scler. 2006 ; 12: 826-829